A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Crohn's disease calm gut inflammation.

Recruiting now. Registry record last updated March 30, 2026.

Who can join: Adults 18+, have Crohn's disease, BMI 27+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor University of MiamiDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 24

What this study is for

Primary condition: Crohn Disease.

Full scientific study title: Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have Crohn's disease, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Adult patients (≥18 years old)
Confirmed diagnosis of Crohn's disease
Mildly active disease, defined by clinical symptoms using the Harvey Bradshaw Index (HBI) score between 5 and 7 (the HBI is a continuous score ranging from 0-16 where \<4 is considered remission)
BMI ≥ 27 kg/m2
Patients will be on stable doses of medical therapy (anti-tumor necrosis factor (TNF) alpha blockers)

Key exclusion criteria

Patients under 18 years of age
Patients with ulcerative colitis
Patients with infectious colitis
BMI\<27 kg/m2
Patients with type 1 or type 2 diabetes

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Florida1 site

University of Miami
Miami, Florida
Michael Mijares, CRC305-243-6405mmijares74@med.miami.edu

Follow this trial

We email you if NCT06774079 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: March 5, 2025. Expected completion: March 5, 2027. Last updated on ClinicalTrials.gov: March 30, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.